{
  "source": "PA-Notification-Duvyzat.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1453-1\nProgram Prior Authorization/Notification\nMedication Duvyzat™ (givinostat) oral suspension\nP&T Approval Date 7/2024\nEffective Date 10/1/2024\n1. Background:\nDuvyzat (givinostat) is a histone deacetylase inhibitor indicated for the treatment of Duchenne\nmuscular dystrophy (DMD) in patients 6 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Duvyzat will be approved based upon both of the following criteria:\na. Diagnosis of Duchenne muscular dystrophy (DMD)\n-AND-\nb. Patient is 6 years of age or older\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Duvyzat will be approved based on the following criterion:\na. Documentation of positive clinical response to Duvyzat therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. Reference:\n1. Duvyzat [package insert]. Concord, MA: ITF Therapeutics, LLC; March 2024.\nProgram Prior Authorization/Notification - Duvyzat (givinostat)\nChange Control\n7/2024 New program\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}